Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lidocaine/epinephrine transdermal - Vyteris

Drug Profile

Lidocaine/epinephrine transdermal - Vyteris

Alternative Names: LidoSite

Latest Information Update: 06 Jun 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vyteris
  • Class Acetanilides; Analgesics; Catecholamines; Local anaesthetics; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Opioid receptor agonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain

Most Recent Events

  • 29 May 2013 Vyteris plans to sell transdermal drug delivery patents, subject to approval of US Bankruptcy Court
  • 14 Aug 2007 Vyteris launches lidocaine/epinephrine transdermal in the US physician's office market
  • 12 Jun 2007 Lidocaine/epinephrine transdermal marketing rights licensed to Laboratory Corporation of America Holdings (LabCorp) in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top